India · Delayed Price · Currency is INR Indoco Remedies Earnings Call Transcripts
Fiscal Year 2026
-
Q4 saw a strong turnaround with 25.8% YoY standalone revenue growth, led by international formulations, while domestic business was muted due to seasonality. Debt remains high but is being managed, and no major CapEx is planned as focus shifts to operational efficiency and margin improvement.
-
Q3 FY26 saw strong export and API growth, improved subsidiary performance, and higher gross margins. Europe and OTC businesses are set for robust growth, while one-time costs from regulatory issues impacted results. Debt reduction and margin improvement remain key priorities.
-
Q2 FY26 saw strong revenue growth and margin recovery, driven by robust India and emerging market performance, new product launches, and operational improvements. USFDA remediation and subsidiary losses remain key risks, but management expects further growth, margin expansion, and limited CapEx ahead.
-
Q1 FY26 saw sequential revenue and EBITDA improvement, driven by OTC and emerging markets, despite ongoing FDA remediation and flat domestic formulations. Debt reduction and cost control efforts continue, with all plants expected fully operational by Q3.
Fiscal Year 2025
-
Operational disruptions, regulatory setbacks, and heavy investments led to a challenging year with declining revenues and margins. Recovery is expected from Q2 as manufacturing normalizes, with strong domestic growth and OTC expansion anticipated.
-
Q3 FY25 saw a sharp revenue and margin decline due to supply disruptions in regulated markets, mainly from a US FDA warning letter and remediation activities. Domestic business remained strong, with key brands outperforming and new launches contributing to growth. Remediation costs and margin pressure are expected to persist for at least two more quarters.
-
Q2 FY25 saw muted revenue growth and margin compression due to plant upgrades and FDA remediation, impacting international sales. Domestic business grew modestly, while OTC and new product launches showed promise. Plant upgrades are nearing completion, with improved performance expected from Q4.
-
Q1 FY25 saw modest revenue decline and margin compression due to US supply constraints and product mix, but strong growth in key brands and new launches. Remediation and CapEx initiatives are expected to drive margin recovery and robust growth in US, Europe, and emerging markets from Q3 onward.